Atay Oguzhan sold $2.7M of BLLN
Atay Oguzhan (Chairman and CEO) sold 25,001 shares of BillionToOne, Inc. (BLLN) at an average of $109.24 ($107.31–$112.44, $2.73M total) across 12 trades on 2026-11-02 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The market may react negatively to the loss of insider ownership, especially in a micro‑cap where insider holdings are closely watched.
Market read
Primary insider sale disclosure; short‑term price impact possible.
What to watch
Potential upcoming financing or strategic moves not disclosed; the sale could free up shares for future transactions.
Background
Form 4 filings provide the first public disclosure of insider transactions. This filing reveals the CEO fully exited his position.
Ticker impact
Chairman and CEO Atay Oguzhan sold 25,001 shares for $2.73M via a 10b5‑1 plan, reducing his stake to zero.
likely downward pressure as the market prices the insider divestment
A $2.7M sale by the CEO is material for a micro‑cap and often triggers short‑term selling, though the transaction was pre‑arranged.
Market effects
Minimal; the sale is company‑specific and does not affect the broader biotech sector.
None; the filing is a US SEC disclosure with no regional macro implications.
Low; only relevant to investors in BLLN.
Counterpoint
The sale was pre‑arranged under a 10b5‑1 plan, so it may not reflect a change in outlook; investors could view it as neutral.
Key entities
- companyBillionToOne, Inc.
Biotech firm listed on NASDAQ under ticker BLLN.
- personAtay Oguzhan
Chairman and CEO of BillionToOne, Inc.

